Tin tức & Cập nhật
Lọc theo Chuyên ngành:
DESTINY-Breast03 reports longest OS in previously treated HER2-positive mBC
Long-term follow-up of the DESTINY-Breast03 trial has reported a median overall survival (OS) of 52.6 months with trastuzumab deruxtecan (T-DXd), representing the longest reported OS in previously treated HER2-positive metastatic breast cancer (mBC) to date.
DESTINY-Breast03 reports longest OS in previously treated HER2-positive mBC
12 Jul 2024
TMI, fludarabine, melphalan pass phase I trial as conditioning therapy in multiple myeloma
Fludarabine, melphalan, and total marrow irradiation (TMI) 900 cGy may be utilized as conditioning for allogeneic stem cell transplantation in patients with high-risk or relapsed/refractory multiple myeloma, as shown in a phase I trial.
TMI, fludarabine, melphalan pass phase I trial as conditioning therapy in multiple myeloma
10 Jul 2024
Nomogram predicts acute radiation enteritis in cervical cancer
A nomogram model displays a decent performance in predicting grade ≥2 acute radiation enteritis (ARE) among patients with cervical cancer receiving concurrent chemoradiotherapy, a study has shown.
Nomogram predicts acute radiation enteritis in cervical cancer
10 Jul 2024
Bulky tumours in PCNSL tied to high local treatment failure
Systemic and intrathecal therapies are necessary for local control in patients with primary central nervous system lymphoma (PCNSL), but bulky tumours remain a problem, according to a study.
Bulky tumours in PCNSL tied to high local treatment failure
10 Jul 2024![[Infographic] Tháng 7 - Cùng nâng cao nhận thức về Sarcoma](https://prdmspst.blob.core.windows.net/images/articles/nang-cao-nhan-thuc-ve-sarcoma-73399196-70ef-4aa6-897d-27a39151b4ec-square.png)
![[Infographic] Một số câu hỏi thường gặp về Nghiên cứu WHI – Sáng kiến về sức khỏe phụ nữ](https://prdmspst.blob.core.windows.net/images/articles/nghien-cuu-whi-69ee3539-1c12-4ced-98c2-25fa5fbdaf89-square.png)
![[NEWS] Dịch vụ Y tế Quốc gia Anh (NHS): bệnh nhân đầu tiên được thử nghiệm điều trị với vaccine cá nhân hóa chống lại ung thư](https://prdmspst.blob.core.windows.net/images/articles/vaccine-ung-thu-đai-truc-trang-3b9416a5-e51d-497e-836b-f6f4c0d4606f-square.png)
Mutations affect efficacy of avelumab in advanced endometrial cancer
Avelumab immunotherapy may perform poorly in advanced endometrial cancer (EC) patients with TP53 mutation but has positive effects in those with mutations of PTEN and ARID1A, suggest the results of the MITO END-3 trial.